Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0F6YK
|
|||
| Former ID |
DCL000133
|
|||
| Drug Name |
Implitapide
|
|||
| Synonyms |
Implitapide [INN]; (2S)-2-cyclopentyl-2-[3-[(2,4-dimethylpyrido[2,3-b]indol-9-yl)methyl]phenyl]-N-[(1R)-2-hydroxy-1-phenylethyl]acetamide
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hyperlipidaemia [ICD-11: 5C80; ICD-10: E78.5] | Phase 2 | [1] | |
| Company |
MRL international
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C35H37N3O2
|
|||
| Canonical SMILES |
CC1=CC(=NC2=C1C3=CC=CC=C3N2CC4=CC(=CC=C4)C(C5CCCC5)C(=O)NC(CO)C6=CC=CC=C6)C
|
|||
| InChI |
1S/C35H37N3O2/c1-23-19-24(2)36-34-32(23)29-17-8-9-18-31(29)38(34)21-25-11-10-16-28(20-25)33(27-14-6-7-15-27)35(40)37-30(22-39)26-12-4-3-5-13-26/h3-5,8-13,16-20,27,30,33,39H,6-7,14-15,21-22H2,1-2H3,(H,37,40)/t30-,33-/m0/s1
|
|||
| InChIKey |
AMNXBQPRODZJQR-DITALETJSA-N
|
|||
| CAS Number |
CAS 177469-96-4
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Microsomal triglyceride transfer protein (MTTP) | Target Info | Inhibitor | [2], [3], [4] |
| KEGG Pathway | Fat digestion and absorption | |||
| Reactome | Chylomicron-mediated lipid transport | |||
| WikiPathways | Statin Pathway | |||
| Lipid digestion, mobilization, and transport | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT00080132) Implitapide in Patients With Hypertriglyceridemia (HTG) on Maximal, Concurrent Triglyceride-Lowering Therapy. U.S. National Institutes of Health. | |||
| REF 2 | Novel nonstatin strategies to lower low-density lipoprotein cholesterol. Curr Atheroscler Rep. 2009 Jan;11(1):67-70. | |||
| REF 3 | Lipid-lowering drugs. Cell Mol Life Sci. 2006 May;63(10):1165-78. | |||
| REF 4 | Implitapide, a microsomal triglyceride transfer protein inhibitor, reduces progression of atherosclerosis in apolipoprotein E knockout mice fed a Western-type diet: involvement of the inhibition of postprandial triglyceride elevation. Biol Pharm Bull. 2005 Feb;28(2):247-52. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.